- Home
- DHF vs CHRS Comparison
DHF vs CHRS Comparison
Compare DHF & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHF
- CHRS
- Stock Information
- Founded
- DHF 1998
- CHRS 2010
- Country
- DHF United States
- CHRS United States
- Employees
- DHF N/A
- CHRS N/A
- Industry
- DHF Finance Companies
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DHF Finance
- CHRS Health Care
- Exchange
- DHF Nasdaq
- CHRS Nasdaq
- Market Cap
- DHF 172.4M
- CHRS 84.2M
- IPO Year
- DHF N/A
- CHRS 2014
- Fundamental
- Price
- DHF $2.59
- CHRS $0.95
- Analyst Decision
- DHF
- CHRS Buy
- Analyst Count
- DHF 0
- CHRS 3
- Target Price
- DHF N/A
- CHRS $4.68
- AVG Volume (30 Days)
- DHF 451.1K
- CHRS 1.3M
- Earning Date
- DHF 01-01-0001
- CHRS 08-07-2025
- Dividend Yield
- DHF 7.65%
- CHRS N/A
- EPS Growth
- DHF N/A
- CHRS N/A
- EPS
- DHF N/A
- CHRS N/A
- Revenue
- DHF N/A
- CHRS $272,251,000.00
- Revenue This Year
- DHF N/A
- CHRS N/A
- Revenue Next Year
- DHF N/A
- CHRS $99.43
- P/E Ratio
- DHF N/A
- CHRS N/A
- Revenue Growth
- DHF N/A
- CHRS 19.87
- 52 Week Low
- DHF $2.06
- CHRS $0.66
- 52 Week High
- DHF $2.39
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- DHF 57.22
- CHRS 59.04
- Support Level
- DHF $2.56
- CHRS $0.73
- Resistance Level
- DHF $2.61
- CHRS $0.82
- Average True Range (ATR)
- DHF 0.03
- CHRS 0.04
- MACD
- DHF -0.00
- CHRS 0.02
- Stochastic Oscillator
- DHF 68.75
- CHRS 88.02
About DHF BNY Mellon High Yield Strategies Fund
BNY Mellon High Yield Strategies Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income and its secondary objective is capital appreciation. It invests predominantly in fixed-income securities of below-investment-grade credit quality.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.